Gilead Sciences (GILD) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Gilead reports positive HIV PrEP data for lenacapavir
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
WPBF2 天
Lake Worth scientist seeing product help athletes deal with and prevent concussions
But a Lake Worth scientist and inventor has a product on the market that he says helps athletes deal with and prevent ...
LGBTQ Nation23 天
Biden administration adds injectable PrEP requirement for insurance providers
Truvada in pill form was the first prescriptive PrEP to hit the market, followed by Descovy. The injectable PrEP Apretude was approved in 2021. HIV+ Hepatitis Policy Institute’s Schmid said the ...
The Pharma Letter25 天
Gilead and Merck tout first weekly oral HIV treatment
US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an ...
FiercePharma29 天
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
The drug offers an alternative to daily pills such as Gilead’s Truvada and its follow-on Descovy. In the Trio Health cohort being presented at IDWeek 2024, there were zero HIV diagnoses among ...